Plant closure hurts Orchid's earnings; J&J comes up with more Doxil;

> Indian API-maker Orchid Chemicals & Pharmaceuticals reported dismal results in its last quarter, in part because a plant in India was closed after pollution concerns. Story

> Johnson & Johnson ($JNJ), which has restricted Doxil treatment to current cancer patients because of manufacturing problems at the Ben Venue Laboratories plant where it was made, now has a limited supply that will be made available for up to 2,000 new patients. News

> Contract manufacturer Angel Biotechnology Holdings ($ABH) has paid £200,000 ($320,470) for a 6,500-square-foot biomaterial and collagen manufacturing plant in Glasgow, U.K., to make purified GMP medical-grade collagen. Release

> With a new plant in China, Danish biotech group Novozymes is now producing hyaluronic acid for pharmaceutical manufacturers. More

> The International Conference on Harmonisation (ICH) has sent its Q11 guidelines on API manufacturing to regulators in the U.S., EU and Japan in an effort to standardize applications. Item

> API-maker Flamma Italy has bought a plant near Milan that will allow it to handle industrial production of triphosgene and ammonia gas. Article

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

Already knocked by the FDA four times this year, Dr. Reddy’s now has a fifth Form 483 to dwell on. This time it’s at a plant with a history of faults.

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.